|
USA-UT-NULL Azienda Directories
|
Azienda News:
- Johnson Johnson: Changing health for humanity
Johnson Johnson Innovative Medicine is leading where medicine is going Patients inform and inspire our science-based innovations, which continue to change and save lives With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow
- Johnson Johnson (JNJ)
Find the latest Johnson Johnson (JNJ) stock quote, history, news and other vital information to help you with your stock trading and investing
- JNJ Stock Price | Johnson Johnson Stock Quote (U. S. : NYSE) - MarketWatch
JNJ | Complete Johnson Johnson stock news by MarketWatch View real-time stock prices and stock quotes for a full financial overview
- Investor Relations | Johnson Johnson
At Johnson Johnson, we believe health is everything Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to s
- Johnson Johnson Common Stock (JNJ) Stock Price, Quote, News History . . .
Discover real-time Johnson Johnson Common Stock (JNJ) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions Stay ahead with Nasdaq
- JNJ | Johnson Johnson Stock Overview (U. S. : NYSE) - Barrons
Complete Johnson Johnson stock information by Barron's View real-time JNJ stock price and news, along with industry-best analysis
- JNJ Stock Quote Price and Forecast - CNN
View Johnson Johnson JNJ stock quote prices, financial information, real-time forecasts, and company news from CNN
- Our company - Johnson Johnson
At Johnson Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress That’s why for almost 140 years, we have aimed to keep people well at every age and every stage of life Today we are committed to using our reach and size for good
- Corporate | Johnson Johnson - investor. jnj. com
1-800-950-5089 investor-relations@its jnj com About us Leadership Team; Office of The Chief Medical Officer; Announcements; Media Center; Our commitments Code of Business Conduct; Environment, Social, Governance; Sustainability; Get in touch Contact Us; Follow us on Youtube; Follow us on Facebook;
- New results for Johnson Johnson’s bleximenib demonstrate promising . . .
About Bleximenib (JNJ-75276617) Bleximenib is an investigational oral menin inhibitor being evaluated for the treatment of patients with newly diagnosed and relapsed or refractory AML It targets a key oncogenic interaction between menin and KMT2A fusion proteins, disrupting a pathway that drives leukemic cell growth in patients with KMT2Ar or
|
|